1. Therapy Areas
  2. Haematology
  4. Vaso-occlusion, VOCs and end-organ damage

Vaso-occlusion, VOCs and end-organ damage

   

VOCs are a major burden of SCD1

Vaso‑occlusion and VOCs can have a range of clinical complications1–4

Ongoing vaso‑occlusion and recurrent VOCs are associated with decreased quality of life, end-organ damage, multiorgan failure and death

 

Abbreviations: RBC, red blood cell; SCD, sickle cell disease; VOCs, vaso-occlusive crises.

References

  1. Conran N, et al. Hemoglobin. 2009;33(1):1–16.
  2. Rees DC, et al. Lancet. 2010;376(9757):2018–2031.
  3. Piel FB, et al. N Engl J Med. 2017;376(16):1561–1573.
  4. Puri L, et al. Paediatr Drugs. 2018;20(1):29–42.
  5. Saidkasimova S, et al. Eur J Ophthalmol. 2016;26(5):431–435.
  6. Liem RI, et al. Pediatr Blood Cancer. 2009;52(7):842–846.
  7. Sachdev V, et al. J Am Coll Cardiol. 2007;49(4):472–479.
  8. Nath KA, Hebbel RP. Nat Rev Nephrol. 2015;11(3):161–171.
  9. Crane GM, Bennet NE. Anemia. 2011;2011:297–364.
  10. Smith-Whitley K. Blood. 2014;124(24):3538–3542.
  11. Thust SC, et al. Br J Radiol. 2014;87:20130699.
  12. Vichinsky EP, et al. N Engl J Med. 2000;342(25):1855–1865.
  13. Gladwin MT, et al. N Engl J Med. 2004;350(9):886–895.
  14. Shah R, et al. World J Gastrointest Pathophysiol. 2017;8(3):108–116.
  15. Koskinas J, et al. Scand J Gastroenterol. 2007;42:499–507.
  16. Sanders WJ. BMC Hematol. 2018;18:5.
UK | April 2021 | 104283
Haematology
Article
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]